June 4, 2020 07:30 AM EDTUpdated 07:40 AM

GSK presents case to expand use of its lupus drug in patients with kidney disease, but the field is evolving. How long will the monopoly last?

Natalie Grover

Reporter

In 2011, GlaxoSmithKline’s Benlysta became the first biologic to win approval for lupus patients. Nine years on, the British drugmaker has unveiled detailed positive results …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

GSK presents case to expand use of its lupus drug in patients with kidney disease, but the field is evolving. How long will the monopoly last?

Natalie Grover

Reporter

Sign up to read this article for free.

Sage sues Biogen days after $469M buyout offer

FDA approves AstraZeneca and Daiichi Sankyo’s ADC for breast cancer despite lack of survival benefit

Ozempic makes list for next round of Medicare drug price negotiations

Kathy High leads GV, ARCH-backed eye disease biotech; Arvinas commercial exec steps down

Novo claims high-dose Phase 3 Wegovy win but sales impact might be muted

What Trump's CMS can and can't change with the second round of drug price negotiations

GSK presents case to ex­pand use of its lu­pus drug in pa­tients with kid­ney dis­ease, but the field is evolv­ing. How long will the mo­nop­oly last?

Natalie Grover

Reporter

Sign up to read this article for free.

more like this

Sage sues Bio­gen days af­ter $469M buy­out of­fer

FDA ap­proves As­traZeneca and Dai­ichi Sankyo’s ADC for breast can­cer de­spite lack of sur­vival ben­e­fit

Ozem­pic makes list for next round of Medicare drug price ne­go­ti­a­tions

Kathy High leads GV, ARCH-backed eye dis­ease biotech; Arv­inas com­mer­cial ex­ec steps down

No­vo claims high-dose Phase 3 We­govy win but sales im­pact might be mut­ed

What Trump's CMS can and can't change with the sec­ond round of drug price ne­go­ti­a­tions

GSK presents case to expand use of its lupus drug in patients with kidney disease, but the field is evolving. How long will the monopoly last?

Sage sues Biogen days after $469M buyout offer

FDA approves AstraZeneca and Daiichi Sankyo’s ADC for breast cancer despite lack of survival benefit

Ozempic makes list for next round of Medicare drug price negotiations

Kathy High leads GV, ARCH-backed eye disease biotech; Arvinas commercial exec steps down

Novo claims high-dose Phase 3 Wegovy win but sales impact might be muted

What Trump's CMS can and can't change with the second round of drug price negotiations